RecallDepth
Class II Ongoing

Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA,

Company
Leo Pharma Inc
Recall Initiated
February 10, 2026
Posted
March 4, 2026
Recall Number
D-0339-2026
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
11,407 units
Firm Location
Madison, NJ, United States

Reason for Recall

Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Distribution

Nationwide in the USA

Lot / Code Info

Lot: a) 003E24C, Exp 04/30/2027; b) 003E24A, Exp 04/30/2027.

More recalls by Leo Pharma Inc

View all recalls by this company →

Other recent Class II Drug recalls